Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 9 Nov 2026
Promising but preliminary

Efficacy and safety of stereotactic body radiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.

Stereotactic body radiotherapy (SBRT) may augment antitumor immunity when combined with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC), but clinical studies span markedly different disease stages and treatment intents and have produced inconsistent comparative results. Although the primary DCR estimate was statistically significant, its sensitivity to individual studies and the low certainty of evidence preclude a firm efficacy conclusion.

Stereotactic body radiotherapy (SBRT) may augment antitumor immunity when combined with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC), but clinical studies span markedly different disease stages and treatment intents and have produced inconsistent comparative results. Although the primary DCR estimate was statistically significant, its sensitivity to individual studies and the low certainty of evidence preclude a firm efficacy conclusion.

What the study was

Study design
Meta-analysis
Population
n=1096
Sample size
n=1096
Category
Other
Maturity
Potentially Practice-Changing
Journal
Translational lung cancer research

Why it surfaced

⚪ PROMISING_PRELIMINARY — Promising but preliminary; Watchlist: Novel therapeutics: immunotherapy, CAR-T, targeted therapy; Design: Meta-analysis; species: human

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.